{"id":"nct:NCT04777396","kind":"trial","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)","authors":["Novo Nordisk A/S"],"author_count":1,"year":2021,"published":"2021-03-02","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT04777396","source_url":"https://clinicaltrials.gov/study/NCT04777396","archive_url":"https://space-kitty.com/papers/nct:NCT04777396","updated":"2026-07-07","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a \"dummy\" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Early Alzheimer's Disease"],"details":{"acronym":"EVOKE","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1840,"sponsor":"Novo Nordisk A/S","conditions":["Early Alzheimer's Disease"],"interventions":["DRUG: Semagludtide","DRUG: Placebo (semaglutide)"],"start_date":"2021-05-18","start_date_type":"ACTUAL","primary_completion_date":"2025-09-16","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}